Nina Schooler
#131,478
Most Influential Person Now
American psychologist
Nina Schooler's AcademicInfluence.com Rankings
Download Badge
Psychology
Nina Schooler's Degrees
- Bachelors Psychology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Nina Schooler Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nina R. Schooler is an American psychologist. She is a professor in the Department of Psychiatry and Behavioral Sciences at SUNY Downstate Medical Center, as well as a founding member of the Brain and Behavior Research Foundation's scientific council. She is known for her research on the treatment of schizophrenia, as well as tardive dyskinesia and first-episode psychosis. She is a past president of the American Psychopathological Association and of the Association for Clinical Psychosocial Research. She previously worked at the National Institute of Mental Health and the University of Pittsburgh. The American Society of Clinical Psychopharmacology established the Nina Schooler Early Career Research Award in her honor.
Nina Schooler's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Research diagnoses for tardive dyskinesia. (1982) (902)
- Physical health monitoring of patients with schizophrenia. (2004) (829)
- Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. (2016) (538)
- Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. (1974) (493)
- Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? (2007) (403)
- The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. (2007) (390)
- Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression (2018) (384)
- Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. (1979) (357)
- Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. (2005) (350)
- Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. (1997) (314)
- Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. (2014) (313)
- Guidelines for depot antipsychotic treatment in schizophrenia (1998) (312)
- SAFTEE: a technique for the systematic assessment of side effects in clinical trials. (1986) (310)
- Changes in caudate volume with neuroleptic treatment (1994) (291)
- The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. (2007) (287)
- The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. (2004) (280)
- Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. (1974) (261)
- Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. (2015) (258)
- Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. (1977) (221)
- Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment (2020) (220)
- Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? (1998) (202)
- Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. (2003) (198)
- Correlates of insight in first episode psychosis (2004) (182)
- Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. (2001) (177)
- Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. (2003) (168)
- The prevalence of tardive dyskinesia. (1991) (167)
- Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. (2003) (166)
- Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. (1980) (163)
- The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. (2015) (159)
- Effectiveness of switching from antipsychotic polypharmacy to monotherapy. (2011) (157)
- Emergence of obsessive compulsive symptoms during treatment with clozapine. (1992) (157)
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? (2008) (152)
- Relapse and rehospitalization: comparing oral and depot antipsychotics. (2003) (148)
- First-episode studies in schizophrenia: criteria and characterization. (1992) (136)
- Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. (2011) (134)
- Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far? (2011) (133)
- Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. (1982) (131)
- The Mount Sinai conference on the pharmacotherapy of schizophrenia. (2002) (129)
- Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. (2004) (129)
- Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II (2003) (120)
- The rationale and ethics of medication-free research in schizophrenia. (1997) (118)
- Dose response of prophylactic antipsychotics. (1993) (117)
- A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. (2009) (114)
- Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. (2006) (113)
- Increased Stroop facilitation effects in schizophrenia are not due to increased automatic spreading activation (1999) (110)
- Neurological examination abnormalities in neuroleptic-naive patients with first-break schizophrenia: preliminary results. (1994) (109)
- Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. (1998) (106)
- A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. (1994) (105)
- Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. (2016) (103)
- The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. (2015) (102)
- Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. (2005) (101)
- Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields (1998) (95)
- Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. (2009) (95)
- One year after discharge: community adjustment of schizophrenic patients. (1967) (94)
- Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. (1998) (92)
- Predictors of Improvement in Tardive Dyskinesia Following Discontinuation of Neuroleptic Medication (1990) (91)
- mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge (2016) (90)
- Duration of Untreated Psychosis in Community Treatment Settings in the United States. (2015) (90)
- Predictors of acute dystonia in first-episode psychotic patients. (1994) (90)
- Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. (2015) (87)
- Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD (2010) (85)
- Ward atmosphere and outcome of treatment of acute schizophrenia. (1967) (85)
- Do clozapine and risperidone affect social competence and problem solving? (2004) (80)
- Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden. (2001) (78)
- Landmark-based morphometric analysis of first-episode schizophrenia (1999) (75)
- Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. (2015) (74)
- A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients (1995) (73)
- The Development of Treatment Resistance in Patients With Schizophrenia: A Clinical and Pathophysiologic Perspective (1998) (72)
- Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital (2002) (71)
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. (2020) (71)
- Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy (2013) (71)
- A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. (2002) (68)
- Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight. (1993) (66)
- Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income (2017) (66)
- Maintenance Medication for Schizophrenia: Strategies for Dose Reduction (1991) (65)
- Predictors of therapeutic response to haloperidol in acute schizophrenia. (1991) (64)
- Relapse prevention and recovery in the treatment of schizophrenia. (2006) (63)
- Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. (2002) (63)
- Tardive dyskinesia. A discontinuation study. (1984) (63)
- An empirical test of a Kraepelinian vs. a Bleulerian view of negative symptoms. (1985) (59)
- The effects of clozapine and risperidone on spatial working memory in schizophrenia. (2005) (59)
- Evidence-based psychosocial treatment for schizophrenia. (2000) (59)
- A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. (2010) (58)
- Duration of untreated psychosis and time to treatment response for delusions and hallucinations. (2005) (57)
- Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. (2015) (57)
- Demographic and clinical correlates of substance use disorders in first episode psychosis (2017) (57)
- Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia (2012) (56)
- Adverse Effects of Risperidone on Eye Movement Activity: A Comparison of Risperidone and Haloperidol in Antipsychotic-Naive Schizophrenic Patients (1997) (55)
- Scientific rewards and conflicts of ethical choices in human subjects research. (1992) (55)
- Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. (1996) (54)
- The clinical research base for the treatment of schizophrenia. (1993) (51)
- Paliperidone Extended-Release in Schizoaffective Disorder: A Randomized, Controlled Study Comparing a Flexible Dose With Placebo in Patients Treated With and Without Antidepressants and/or Mood Stabilizers (2010) (51)
- Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment (1998) (51)
- Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. (2012) (49)
- Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic‐induced deficits (1994) (44)
- Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders". (1998) (41)
- The prevalence of akathisia in patients receiving stable doses of clozapine. (1994) (41)
- Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group. (1989) (40)
- First Administration of Cytidine Diphosphocholine and Galantamine in Schizophrenia: A Sustained &agr;7 Nicotinic Agonist Strategy (2008) (39)
- Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. (2012) (38)
- How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatments for schizophrenia (2014) (37)
- Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. (1980) (36)
- Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis (2011) (36)
- Prediction of response to phenothiazines in schizophrenia. A crossvalidation study. (1972) (36)
- Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning (2005) (35)
- Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. (2017) (35)
- Personality traits in schizophrenia. (1995) (34)
- Effects of behavioural family management on family communication and patient outcomes in schizophrenia (2000) (34)
- Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. (2006) (33)
- Personality dimensions in first-episode psychoses. (2005) (33)
- Psychological well-being and mental health recovery in the NIMH RAISE early treatment program (2017) (33)
- Maintenance medication for schizophrenia: strategies for dose reduction. (1991) (33)
- Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms (2015) (32)
- Efficacy versus effectiveness. (1997) (32)
- The expert consensus guideline series (2009) (32)
- General versus specific inquiry with SAFTEE. (1992) (31)
- Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. (2019) (30)
- Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia (2018) (29)
- Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder (2004) (29)
- A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. (1994) (29)
- PARANOID AND WITHDRAWAL SYMPTOMS IN SCHIZOPHRENIA: DIFFERENTIAL SYMPTOM REDUCTION OVER TIME (1967) (29)
- Research and treatment strategies in first-episode psychoses: The Pittsburgh experience (1998) (28)
- Proceedings: Drug and sociotherapy in the aftercare of schizophrenic patients. (1974) (26)
- A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. (1993) (26)
- Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review. (1995) (26)
- The cultural adaptability of intermediate measures of functional outcome in schizophrenia. (2012) (26)
- Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study (2019) (23)
- Family treatment for schizophrenia : the design and research application of therapist training models. (1996) (23)
- Reducing Dosage in Maintenance Treatment of Schizophrenia (1993) (22)
- Chapter 14: Self-Help Group Participation Among People with Severe Mental Illness (1995) (22)
- Sociotherapy and the prevention of relapse among schizophrenic patients: an artifact of drug? (1976) (22)
- Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects. (2013) (22)
- Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital (2019) (21)
- Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. (1977) (21)
- Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. (2016) (21)
- Evaluation of drug-related movement disorders in the aged. (1988) (21)
- Are Biochemical Markers for Treatment‐Resistant Schizophrenia State Dependent or Traits? (1990) (21)
- Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings]. (1979) (20)
- Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study (2017) (20)
- Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. (1979) (19)
- Research and methods (1998) (19)
- Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis. (2017) (19)
- Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. (1999) (19)
- The efficacy of antipsychotic drugs and family therapies in the maintenance treatment of schizophrenia. (1986) (19)
- Treatment strategies in schizophrenia: Effects of dosage reduction and family management on outcome (1993) (18)
- Predictive value of eosinophilia for neutropenia during clozapine treatment. (1996) (18)
- The Initiation of Long-Term Pharmacotherapy in Schizophrenia: Dosage and Side Effect Comparisons Between Oral and Depot Fluphenazine* (1976) (18)
- Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. (2016) (18)
- Intervention research in psychosis: issues related to clinical assessment. (2000) (18)
- Standards in research: APA's mechanism for monitoring the challenges. (1991) (18)
- The reliability of a shortened version of the SCL-90. (1988) (17)
- Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP. (2019) (16)
- Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy (2008) (16)
- Education of Homeless Children and Youth: Problems and Creative Interventions (1990) (15)
- Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder (2017) (15)
- The role of depot neuroleptics in the treatment of schizophrenic patients (1979) (15)
- Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients. (2014) (15)
- Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? (2017) (14)
- Life history and symptoms in schizophrenia. Severity at hospitalization and response to phenothiazines. (1971) (14)
- Chlorpromazine metabolism and clinical response in acute schizophrenia: a preliminary report. (1975) (13)
- A one-year comparison of four dosages of haloperidol decanoate (1993) (13)
- Efficacy of clozapine versus haloperidol in a long-term clinical trial (1996) (13)
- New antipsychotic medications: strategies for evaluation and selected findings (1997) (12)
- The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). (1996) (12)
- Continuation Electroconvulsive Therapy for Patients With Clozapine-Resistant Schizophrenia: A Pilot Study. (2019) (12)
- Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings (1995) (11)
- Negative symptoms in schizophrenia: assessment of the effect of risperidone. (1994) (11)
- Maintenance treatment of schizophrenia: A review of dose reduction and family treatment strategies (2005) (11)
- Perceived Autonomy Support in the NIMH RAISE Early Treatment Program. (2017) (11)
- Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group. (1989) (11)
- Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. (2016) (11)
- Saftee (systematic Assessment For Treatment Emergent Events). A New Technique For Detecting Side Effects In Clinical Trials (1984) (11)
- A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy. (2009) (11)
- Efficacy of Drug Treatment for Chronic Schizophrenic Patients (1984) (10)
- Clozapine, obsessive symptoms, and serotonergic mechanisms. (1993) (10)
- Paranoid and Withdrawal Symptoms in Schizophrenia: Relationship to Reaction Time (1968) (10)
- Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication. (2012) (9)
- Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. (2016) (9)
- Maintaining symptom control: review of ziprasidone long-term efficacy data. (2003) (9)
- Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS) (2017) (9)
- Treatment, services, and environmental factors. (1988) (9)
- Brief social history for studies in schizophrenia: an announcement of a new data collection instrument. (1972) (9)
- Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). (2019) (9)
- Dosage and side effect comparisons betweel oral and depot fluphenazine. (1977) (8)
- Medication Prescription Practices for the Treatment of First Episode Schizophrenia-Spectrum Disorders: Data from the National RAISE-ETP Study (2015) (8)
- 532 Predictors of response to clozapine in a long-term double blind treatment study (1997) (8)
- Does caudate volume increase during follow up in first-episode psychoses? (1995) (8)
- Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder (2016) (8)
- PROACTIVE: INITIAL RESULTS OF AN RCT COMPARING LONG-ACTING INJECTABLE RISPERIDONE TO 2ND GENERATION ORAL ANTIPSYCHOTICS (2012) (8)
- Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. (2004) (7)
- The influence of family management of patient stabilization (1989) (7)
- Sex and race differences in response to drug treatment among schizophrenics (2004) (7)
- Strategies for enhancing drug therapy of schizophrenia. (1983) (7)
- How generalizable are the results of clinical trials? (1980) (6)
- The impact of clozapine on psychosocial competence (1995) (6)
- New drug treatment strategies in schizophrenia: editorial introduction. (1983) (6)
- Stabilization and depot neuroleptic dosages. (1993) (6)
- Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia (2016) (6)
- Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial (2020) (6)
- Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis (2017) (5)
- Advances in Maintenance Treatment (1996) (5)
- Gerard E. Hogarty (1935--2006): combining science and humanism to improve the care of persons with schizophrenia. (2007) (5)
- P.2.132 Reduced relapse rates in recent onset schizophrenia patients treated with risperidone vs. haloperidol (2003) (5)
- Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review (1995) (5)
- Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial (2017) (5)
- Gray matter volume deficits in first-episode schizophrenia (1994) (5)
- Ensuring data quality in a multicenter clinical trial: remote site data entry, central coordination and feedback. (1989) (5)
- T255. WHO PARTICIPATED IN FAMILY WORK IN THE US RAISE-ETP FIRST EPISODE SAMPLE? (2018) (5)
- Neuroleptics and psychosocial treatments: a discussion. (1980) (5)
- A cognitive neuropsychological study of schizophrenia symptoms: Correlates of stroop and semantic priming performance (1995) (4)
- Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions (2003) (4)
- The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics (1996) (4)
- Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. (2019) (4)
- The Efficacy and Safety of Conventional and Atypical Antipsychotics in First-Episode Schizophrenia: A Review of the Literature (2007) (4)
- Ziprasidone's effect on anxiety in a group of outpatients with stable schizophrenia (2000) (4)
- MRI abnormalities in first-episode schizophrenia: Association with neurological impairment (1995) (3)
- Performance tests in a study of phenothiazines in schizophrenia: Caveats and conclusions (2004) (3)
- 545 Efficacy of risperidone in first-episode schizophrenia (1997) (3)
- Implications for future research of "medication-free research in early episode schizophrenia". (2006) (3)
- 761. Continuation Electroconvulsive Therapy for Clozapine-Resistant Schizophrenia (2017) (3)
- 530 First improvement with clozapine: How patient should we be? (1997) (3)
- 197. Decreased caudate volume in first episode schizophrenia (1996) (3)
- The statistical comparison of clinical trials. (2001) (3)
- Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP) (2020) (3)
- Tolerability of clozapine and risperidone during a twenty nine week trial (2003) (2)
- Relapse prevention through health technology program reduces hospitalization in schizophrenia (2019) (2)
- An Exploratory Study of Exercise-related Effects on Memory and Hippocampal Connectivity in Schizophrenia. (2018) (2)
- 65-88 The FutuRIS study — A prospective long-term evaluation of risperidone versus haloperidol in early psychosis patients (1997) (2)
- Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D). (2022) (2)
- Cognitive behavioural therapy for clozapine non-responders. (2018) (2)
- Tardive dyskinesia workgroup report. (1980) (2)
- C.16.03 Negative symptoms in schizophrenia: identification, assessment and intervention (2008) (2)
- 43. Cognitive Functioning in First-Episode Psychosis:_x000B_ Comparison of a 2-Year Coordinated Specialty Care Program to Community Care (2017) (2)
- O4.5. LONG TERM EFFECTS OF EARLY INTERVENTION SERVICES FOR FIRST EPISODE PSYCHOSIS: OUTCOMES OVER FIVE YEARS FROM THE RECOVERY AFTER A 1ST EPISODE OF SCHIZOPHRENIA-EARLY TREATMENT PROGRAM (RAISE-ETP) (2020) (2)
- Morphology of the corpus callosum in first-break schizophrenic patients: An MRI study (1995) (2)
- Schizophreniform disorder: exception proves the rule. (1999) (2)
- Precursors to the PANSS: The BPRS and its progenitors. (2017) (2)
- Efficacy of clozapine vs. haloperidol in a long-term clinical trial: Preliminary results (1995) (2)
- Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods (1996) (2)
- Attention, semantic processing, and symptoms in schizophrenia (1995) (2)
- 764 Clozapine vs. haloperidol: Drug intolerance in a controlled six month trial (1997) (2)
- Psychosocial Treatment: More Than Compassion and Common Sense? (2000) (2)
- HIGH RISK RESEARCH (2014) (1)
- Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. (2022) (1)
- P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder (2014) (1)
- Cerebellar and vermal volume in first-break schizophrenia (1995) (1)
- Proceedings: Sex and race differences in symptomatology of schizophrenic outpatients associated with clinical relapse. (1974) (1)
- Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial (2020) (1)
- Long-Term Outcomes of Psychosis: Naturalistic Follow-Up After Initial Hospitalization. (2017) (1)
- Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR? (2012) (1)
- Clozapine and risperidone in moderately refractory schizophrenia: A six month double-blind comparison (2003) (1)
- SHARED CONTRIBUTIONS OF COMMON GENETIC VARIANTS TO RISK OF PSYCHOSIS AMONG INDIVIDUALS OF AFRICAN, LATINO, AND EUROPEAN ANCESTRY (2019) (1)
- Is there arrested development of the corpus callosum in first-break schizophrenic patients? (1995) (1)
- A basis for optimism — The implications of long-term treatment (1998) (1)
- P.2.124 Treatment of cognitive impairment in recent onset psychosis; a comparison of risperidone and haloperidol (2003) (1)
- 525 Effectiveness of clozapine in treatment resistant schizophrenia (1997) (1)
- 330. Atypical antipsychotic effects on fMRI in drug-naive schizophrenia (2000) (1)
- 199. Comparing new anti-psychotic medications: What do the data say? (1998) (1)
- Dr. Mueser and Colleagues Reply (1996) (1)
- Editor's concluding remarks: psychosocial treatment: more than compassion and common sense? (2000) (1)
- 285 Rapid and gradual reconstitutive processes in schizophrenia (1997) (1)
- Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP Results. (2016) (1)
- New medications for schizophrenia: Therapeutic impact and side effects (1993) (0)
- Invited commentary: “Everybody has won, and all must have prizes” (Carroll, 1865) (2019) (0)
- Jonathan O. Cole, MD (1925-2009): Innovator in clinical psychopharmacology and of the ECDEU/NCDEU tradition. (2011) (0)
- Pharmacologic treatment for mental illness. (1990) (0)
- Translating treatment research findings into clinical action. (1994) (0)
- Authors' reply (2001) (0)
- O4.2. THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN FIRST EPISODE AND EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE PRELAPSE TRIAL (2020) (0)
- P.3.d.060 Efficacy of lurasidone in the treatment of schizophrenia with prominent negative symptoms: a post-hoc analysis of five short-term trials (2014) (0)
- Depressive symptomatology, negative symptoms and extrapyramidal symptoms (EPMS) in acute treatment response and short term outcome (1989) (0)
- Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A). (2023) (0)
- Psychopharmacotherapy: Side Effects (2001) (0)
- LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS IN SCHIZOPHRENIA: DO RECENT STUDIES CHANGE OUR UNDERSTANDING OF THEIR ROLE IN OUR TREATMENT ARMAMENTARIUM? (2012) (0)
- Interrater reliability of the neurological evaluation scale (1995) (0)
- Relapse in Schizophrenia-Reply (1981) (0)
- Multiple Facets of Schizophrenia (2005) (0)
- Gerard E Hogarty, 1935–2006 (2006) (0)
- Remote Assessment of Negative Symptoms of Schizophrenia (2023) (0)
- P3.e.023 Statistical approaches in a global era: integrating multi-regional studies (2009) (0)
- P.2.051 Ziprasidone negative symptom efficacy in long-term clinical trials (2003) (0)
- P.3.d.019 Lurasidone treatment response in patients with schizophrenia assessed using the DSM-5 dimensions of psychosis severity scale (2015) (0)
- Response to Saraga. (2015) (0)
- TO THEEDITOR: Inagreement withDr. Saraga, we wouldvery much like to interview the prescribers of the medications recordedinoursurveyabouttheirprescribingdecisions.They werenot,asDr.Saragasuggests,"physiciansintheRAISE-ETP (2015) (0)
- Implementation of NAVIGATE Coordinated Specialty Care for First Episode Psychosis: the Michigan Experience. (2021) (0)
- P.3.d.065 Lurasidone treatment response in patients with schizophrenia assessed using the DSM-5 dimensions of psychosis severity scale (2015) (0)
- Relapse prevention through health technology program reduces hospitalization in schizophrenia. (2022) (0)
- Poster #T208 PROACTIVE: EXPLORING LONGITUDINAL SYMPTOM COURSE TO UNDERSTAND OUTCOMES IN LAI-ORAL COMPARISONS (2014) (0)
- Contents of the American Journal of Psychiatry (2004) (0)
- Awareness of mental disorder predicts relapse in a 30-month study of antipsychotic treatment in schizophrenia (2016) (0)
- Contents of the American Journal of Psychiatry (1995) (0)
- Topics in Psychopharmacology. (1990) (0)
- Can we incorporate psychosocial treatment interventions into psychopharmacology clinical trials? (2012) (0)
- 96. Awareness of memory dysfunction in first-episode schizophrenia (2000) (0)
- Cerebral asymmetry, gender, and early schizophrenia (1995) (0)
- fMRI motor effects of atypical antipsychotics in drug-naive schizophrenia (2000) (0)
- VALIDATION OF INTERMEDIATE (CO-PRIMARY) MEASURES FOR CLINICAL TRIALS OF COGNITION-ENHANCING DRUGS FOR SCHIZOPHRENIA (2010) (0)
- Plasma levels of Fluphenazine and prolactin in maintenance treatment of schizophrenia (1989) (0)
- O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE (2020) (0)
- Research training for clinical trials in psychopharmacology. (1988) (0)
- 433. Neurological abnormalities in first episode psychoses (1998) (0)
- 3.03 – Group Comparisons: Randomized Designs (1998) (0)
- C.18.04 Measuring and monitoring patient outcomes -achieving positive outcomes with negative symptoms (2006) (0)
- S.14.04 Early intervention and the course of illness (1996) (0)
- Poster #T187 EFFICACY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA WITH PROMINENT NEGATIVE SYMPTOMS: A POST-HOC ANALYSIS OF SHORT-TERM TRIALS (2014) (0)
- Functional Outcomes of an Antipsychotic Medication in Schizophrenia: A Generalizable or Specific Effect? (2022) (0)
- Haloperidol dosing strategies. (1996) (0)
- FUNCTIONAL OUTCOME AS A LONG-TERM TREATMENT GOAL: DEFINITION AND ASSESSMENT IN CLINICAL TRIALS (2010) (0)
- Factor structure of the neurological evaluation scale (1995) (0)
- Longitudinal study of inflammation and relapse in schizophrenia (2023) (0)
- Association of clinical variables with spect findings in schizophrenia (1993) (0)
- [Role of long-acting neuroleptics in the treatment of schizophrenia]. (1979) (0)
- Single trial stroop versus stroop card measurements in schizophrenia (1995) (0)
- 238. Neurologic exam abnormalities in treatment-naive psychotic mood disorders (1998) (0)
- NDT_A_225643 519..534 (2020) (0)
- Statistical strategies for prediction of clinical response: performance tests as predictors of reduction in psychopathology. (1978) (0)
- F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS (2018) (0)
- Predictors of Hospitalization with Individuals With First-Episode Psychosis: Data From a Two-Year Follow-Up in the RAISE-ETP Study (2019) (0)
- Response to Baandrup Letter (2011) (0)
- New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists. (2012) (0)
- Life History Characteristics of Responders to Drug and Social Therapy in Schizophrenia (1977) (0)
- Solomon C Goldberg, PhD (2008) (0)
- ILOPERIDONE: PLACEBO- AND ZIPRASIDONE-CONTROLLED STUDY IN PATIENTS WITH SCHIZOPHRENIA (2007) (0)
- Postpsychotic Depression-Reply (1983) (0)
- Neuropsychological functions of prefrontal cortex are selectively impaired early in the course of schizophrenia (1995) (0)
- 432. Personality profiles in first episode schizophrenia (1998) (0)
This paper list is powered by the following services:
Other Resources About Nina Schooler
What Schools Are Affiliated With Nina Schooler?
Nina Schooler is affiliated with the following schools:
